MIRA Pharmaceuticals, Inc. — Company profile
Healthcare · Drug Manufacturers - General · United States
Last price 0.5716 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 24.02M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a next-generation oral NMDA receptor modulator, that has completed a Phase 1 clinical trial. It also offers oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia; and SKNY-1, that is in preclinical stage for obesity and nicotine dependence. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is based in Miami, Florida.
Details
| Name | MIRA Pharmaceuticals, Inc. |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Employees | 3 |
| Founded | 2020 |
| Ipo Date | 2023-08-03 |
| Ceo | Erez Aminov |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 7.00 |
| Isin | US60458C1045 |
| Cusip | 60458C104 |
| Cik | 1904286 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Erez Aminov | Chief Executive Officer and Chairman |
| Andriy Mushak CPA | Chief Financial Officer |
| Dr. Itzchak Angel Ph.D. | Chief Scientific Advisor |
Contact
| Address | 1200 Brickell Avenue, Suite 1950 #1183, Miami, Florida 33131, United States |
| Phone | 786 432 9792 |
| Website | https://mirapharmaceuticals.com |